We expect the launch of Agent DCB in Europe to help Boston Scientific improve its presence in the coronary heart disease market in the region. There is huge potential for growth in this market considering that coronary heart disease causes an estimated 1.8 million deaths every year in Europe, making it the single most common cause of death in the region.